You are here: Industry Insights > COPD

News List

Plerixafor may protect against smoke-related COPD symptoms europeanpharmaceuticalreview
July 06, 2018
A drug used in stem cell therapy to treat certain cancers may also protect against cigarette smoke-induced lung injury…
Fasenra Does Not Meet Primary Endpoint in Severe COPD Study americanpharmaceuticalreview
May 18, 2018
AstraZeneca and MedImmune announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
AZ’s Fasenra stumbles in P3 for COPD pharmafile
May 15, 2018
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up indications to mount a serious challenge – in COPD,
myAirvo significantly benefits COPD Patients biospectrumasia
April 23, 2018
The trial is the largest study of this treatment length to have been conducted in a home environment and was led by researchers Line Storgaard and Dr Ulla Weinreich.
Editorial questions study design supporting effectiveness of GlaxoSmithKline, Innoviva's Trelegy Ellipta triple therapy for COPD firstwordpharma
April 20, 2018
An editorial published in the NEJM alongside detailed results from the IMPACT study of GlaxoSmithKline and Innoviva's once-daily single inhaler triple therapy Trelegy Ellipta
Inhaled corticosteroids may increase bone fractures in patients with COPD europeanpharmaceuticalreview
February 12, 2018
A study suggests long-term inhaled corticosteroids (ICS) in patients with COPD may increase the risk of bone fractures in both men and women…
AZ’ triple combo COPD inhaler hits PhIII targets pharmatimes
January 31, 2018
AstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca's Three-in-One COPD Inhaler Succeeds in Phase III Trial biospace
January 29, 2018
AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights.
AZ’ Tudorza hits study goals in COPD patients with CV risk factors pharmatimes
December 06, 2017
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
Inhaled heparin shows potential in lung disease pharmatimes.
December 05, 2017
The veteran bloodthinner heparin has been found in a small UK trial to help improve breathing when inhaled by patients with chronic obstructive pulmonary disease (COPD).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page